Pfizer’s Velsipity UK approval will raise competition in ulcerative colitis market, says GlobalData

The approval marks a significant milestone for the American pharmaceutical company in the field of UC

Abbott receives FDA approval for TriClip

TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery

Sanofi and Cipla enters into distribution partnership to expand reach of CNS portfolio in India

Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium

Cipla appoints Venkata Sai Mungara as Global Head – Supply Chain

Mungara has over 25+ years of experience in the supply chain domain

Sanofi India inks distribution partnership with Emcure to expand reach of its cardiovascular brands

Cipla incorporates JV company in USA

Cipla completes transfer of Generics Business Undertaking

Asahi Kasei offers pharmaceutical excipient Ceolus with nitrite concentration of 0.1 ppm or less

Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals

Pfizer joins hands with NIPER (Ahmedabad) to support Healthcare Innovation in India

Pfizer INDovation program partners with NIPER Ahmedabad to incubate healthcare startups

European Commission approves Pfizer’s Velsipity for patients with moderately to severely active ulcerative colitis

VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU

Evonik, University of Mainz to commercialize a new class of PEG lipids for nucleic acid delivery

Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery